Introduction
Datamonitor believes that RSD1235 (iv) has the potential to have a significant impact on the treatment of atrial fibrillation. In addition, P&G's Stedicor and Sanofi-Aventis' Multaq also offer advances on current treatments, with improvements in efficacy and safety therein.
Scope
Evaluation of patient potential for developmental antiarrhythmics over the period 2006-2015
Scrutiny of key impacts on the R&D approach and cost, evaluation of optimal clinical trial end points and identification of suitable comparators
Evaluation of key players in the arrhthymics market and opposing company approaches to development and commercialization
Analysis of key antiarrhymic drugs in development and their ability to satisfy major unmet needs and compete with existing agents
Report Highlights
2005 saw sales in the antiarrhythmics drug market decline. With key problems of current antiarrhythmic drug therapy surrounding their pro-arrhythmic and toxic side effects, it may be sufficient for developmental compounds to demonstrate equivalent efficacy but superior safety profiles to gain market share from the current genericized treatments.
By 2015 the global antiarrhythmic market will be worth $3.5 billion, with sales of pipeline products accounting for over two thirds of the market by this time. RSD1235 (iv) is predicted to command 27% of the whole market by 2015 on the back of good trial data and the involvement of Astellas in the promotion of the product in the US.
P&G Pharma's Stedicor (azimilide) looks set to become the most successful orally active antiarrhythmic due to a combination of robust late-stage clinical trial data for Stedicor, particularly from the SHIELD (Shock Inhibition Evaluation with Azimilide) study, and lingering concerns over the relative safety of Sanofi-Aventis' Multaq (dronedarone).
Reasons to Purchase
Explore physician attitudes to the newer antiarrhythmic drugs, and the threats faced by existing and developmental products
Predict future market leaders using our independent sales forecasts for products in late stage development in both existing and novel classes
Identify early stage antiarrhythmic compounds with high potential being developed by companies seeking a marketing partner
Pipeline Insight: Antiarrhythmics - RSD1235 in a class of its own is a marketing resource from Datamonitor, a leading provider of online data, analytic and forecasting platforms for key vertical sectors. It helps 5,000 of the world's largest companies profit from better, more timely decisions. 